Background: Identification of factors to detect and improve chemotherapy-response in cancer is the
main concern. microRNA-372-3p (miR-372-3p) has been demonstrated to play a crucial role in cellular proliferation,
apoptosis and metastasis of various cancers including Hepatocellular Carcinoma (HCC). However, its
contribution towards Doxorubicin (Dox) chemosensitivity in HCC has never been studied.
Objective: This study aims to investigate the potential role of miR-372-3p in enhancing Dox effects on HCC cell
line (HepG2). Additionally, the correlation between miR-372-3p and HCC patients who received Transarterial
Chemoembolization (TACE) with Dox treatment has been analyzed.
Methods: Different cell processes were elucidated by cell viability, colony formation, apoptosis and wound
healing assays after miR-372-3p transfection in HepG2 cells Furthermore, the miR-372-3p level has been
estimated in the blood of primary HCC patients treated with TACE/Dox by quantitative real-time PCR assay.
Receiver Operating Curve (ROC) analysis for serum miR-372-3p was constructed for its prognostic significance.
Finally, the protein level of Mcl-1, the anti-apoptotic player, has been evaluated using western blot.
Results: We found a significantly higher level of miR-372-3p in the blood of the responder group of HCC patients
who received TACE with Dox than of non-responders. Ectopic expression of miR-372-3p reduced cell
proliferation, migration and significantly induced apoptosis in HepG2 cells which was coupled with a decrease
of anti-apoptotic protein Mcl-1.
Conclusion: Our study demonstrated that miR-372-3p acts as a tumor suppressor in HCC and can act as a predictor
biomarker for drug response. Furthermore, the data referred for the first time its potential role in drug
sensitivity that might be a therapeutic target for HCC.